Taro Pharmaceutical Indus (NYSE:TARO) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $0.31 by 38.71 percent. The company reported quarterly sales of $164.941 million which beat the analyst consensus estimate of $156.062 million by 5.69 percent. This is a 12.52 percent increase over sales of $146.587 million the same period last year.
Taro Pharmaceutical Indus Q4 Adj EPS $0.43 Beats $0.31 Estimate, Sales $164.941M Beat $156.062M Estimate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.